Non-Alcoholic Fatty Liver Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 20 to 80 years
- People who have been diagnosed with a liver condition called MASLD, which is defined as having fat in the liver combined with excess abdominal fat, measured using international guidelines specific to their country or ethnic background
Who may not be able to join:
- People with significant liver scarring (fibrosis), detected by a special ultrasound scan, a calculated blood test score, or other signs of serious liver complications
- People whose liver enzyme levels (ALT) in the blood are more than three times the normal upper limit
- People who have another liver disease unrelated to MASLD
- People with serious heart or kidney disease, most types of cancer, or other medical conditions that are not well controlled
- People who have any reason they cannot safely have an MRI scan
- People who have previously had a bad reaction or allergy to nicotinic acid (a form of vitamin B3)
- People who have taken part in a research study involving radiation exposure within the two years before this trial starts
- People who are allergic to eggs
- People who smoke more than one cigarette per day, or who drink more than two alcoholic drinks per day
- Women who are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: André Carpentier, MD, Université de Sherbrooke
Phone: 1-819-346-1110
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Prolonged small-dose niacin treatment does not lead to desensitization of the niacin-induced reduction in hepatic total fatty acids flux.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.